Health Discovery Corporation’s New Molecular Diagnostic Test for Prostate Cancer Successfully Performs at 90% Sensitivity and 97% Specificity in Double-Blind Clinical Trial
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells.
No User Responded In This Post
Leave Your Comments Here...